29-Jan-2007 | S | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 29, 2007, inter alia, has considered and approved the following:
1. Approved the sub-division of equity shares from Face Value of Rs 2/- each to Face Value of Rs 1/- each subject to approval of members in general meeting and other approvals, if any.
Suven Life Sciences Ltd has informed BSE that the members at the Extra Ordinary General Meeting (EGM) of the Company held on March 10, 2007, have approved the Sub-division of equity shares from the face value of Rs 2/- each to face value of Re 1.00/- each and issue of Bonus shares 1:1 i.e., one equity share for every one equity share held as on the Record Date.
(As Per BSE Announcement Website Dated on 12/03/2007)
SUB: Sub Division and Bonus issue of equity shares of Suven Life Sciences Limited (Scrip Code 530239)
Trading Members of the Exchange are hereby informed that, Suven Life Sciences Limited has fixed the Record Date for the purpose of sub division and bonus issue.
COMPANY NAME
Suven Life Sciences Limited
CODE
530239
RECORD DATE
02/04/2007
PURPOSE
Sub Division of existing equity shares from every ONE equity share of Rs.2/- each into TWO equity shares of Re.1/- each. AND Issue of ONE bonus equity share for every ONE equity share held.
SUB-DIVIDED PAID-UP VALUE
Re.1/-
SUB-DIVIDED PAID-UP VALUE & EX-BONUS W.E.F.
23/03/2007 DR-248/2006- 2007
The auction in the equity shares of Suven Life Sciences Limited in Dematerialised Securities - Rolling Settlement Segment on 23/03/2007, 26/03/2007 and 28/03/2007 will be conducted as per face value of Rs.2/- each and on cum-bonus basis. Trading members are, therefore, requested to take abundant precautions while mentioning the rates for offering the equity shares of the said company in auction on the said dates.
The scrip will be No Delivery from 23/03/2007 (DR-248/2006-2007) to 30/03/2007 (DR-002/2007-2008).
Note :-
i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Re.1/- paid up w.e.f. 23/03/2007.
ii. ISIN No. INE495B01020 of Rs.2/- paid up will not be valid for transactions done on the Exchange on or after 20/03/2007, except for the auction transactions, which will be conducted on 23/03/2007, 26/03/2007 and 28/03/2007 respectively.
iii. The new ISIN Number for Re.1/- paid up will be informed to the market by a separate notice.
(As Per BSE Notice dated On 13/03/2007)
Trading Members of the Exchange were informed vide Notice No. 20070315-25 dated March 15, 2007 that Suven Life Sciences Limited (Scrip Code: 530239) has sub-divided their equity shares from Rs. 2/- paid up per share to Re. 1/- paid up per share.
In this connection, CDSL has informed the Exchange that the new ISIN. No. INE495B01038 has been allotted for the sub-divided equity shares consequent to sub-division.
(As per BSE Notice dated on 02/04/2007) | 02-Apr-2007 | |
12-Jan-2004 | S | Sub Division of Existing equity shares from every ONE Equity Share of Rs.10/- each into FIVE Equity Shares of Rs.2/- each.
Sub Divided Paid-up Value:Rs.2/-
The auction in the equity shares of Suven Life Sciences Ltd. In Dematerialised Securities-Rolling Settlement Segment on 15/01/2004,16/01/2004 and 19/01/2004 will be conducted as per face value of Rs.10/- each. Members are therefore requested to take abundant precautions while mentioning the rates for offering the equity shares of the said company in auction on the said dates.
The scrip will be No Delivery from 15/01/2004 to 21/01/2004.
Members are hereby informed that the transactions in the equity shares (Physical) of the aforesaid
company in the Exit-Route Scheme will be for Rs.2/- paid up w.e.f 15th January, 2004.
| 23-Jan-2004 | |
05-Feb-2019 | D | Interim Dividend
a) The Board declared an interim dividend of Rs. 1.50 per equity share of face value Rs 1/- each for the year 2018-2019.
b) The Board approved the Record Date i.e., 15th February 2019 notified by the Company for the purpose of payment of interim dividend to the eligible
shareholders.
c) The above said dividend will be paid on and from 25th February, 2019. | 14-Feb-2019 | |
30-Jan-2018 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 30, 2018, inter alia, has approved the following:
1. The Board declared an interim dividend of Rs. 1.50 per equity share of face value Rs. 1/- each for the year 2017-2018.
2. The above said dividend will be paid on and from February 15, 2018. | 06-Feb-2018 | |
01-Feb-2017 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company, at its meeting held on February 01, 2017, has approved the following matters:
1. The Board declared an interim dividend of Rs. 1/- per equity share of face value Rs 1/- each for the year 2016-2017. | 08-Feb-2017 | |
05-Mar-2016 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 05, 2016, inter alia, has approved the following matters:
1. The Board declared an interim dividend of Rs. 1/- per equity share and a onetime special dividend of Rs. 1/- per equity share totaling to Rs. 2/- per equity share of Rs. 1/- each for the year 2015-2016.
2. The above said dividend will be paid on and from March 23, 2016. | 14-Mar-2016 | |
05-Mar-2016 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 05, 2016, inter alia, has approved the following matters:
1. The Board declared an interim dividend of Rs. 1/- per equity share and a onetime special dividend of Rs. 1/- per equity share totaling to Rs. 2/- per equity share of Rs. 1/- each for the year 2015-2016.
2. The above said dividend will be paid on and from March 23, 2016. | 14-Mar-2016 | |
26-May-2015 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2015, inter alia, has proposed a Dividend of Re. 0.60 per share (60% of face value Rs. 1.00 each) for the financial year 2014-15, the dividend will be paid on and from August 28, 2015 to the members, subject to the approval of Members in the ensuing Annual General Meeting.
Further, as required under new PIT Regulations 2015 of SEBI, the Board of Directors has approved the Code on prevention of Insider Trading and Code for fair disclosures with effective date from May 15, 2015 in its meeting held i.e. May 26, 2015. | 23-Jul-2015 | |
22-May-2014 | D | Suven Life Sciences Limited has informed the Exchange that the Board of Directors of the company at its meeting held on May 22,2014 has recommended dividend Re.0.50 paisa per share(50% of face value Rs.1.00 each) with an additional Special Silver Jubilee year dividend of Rs.2.00 per share (200% of face value of Rs.1.00
each), aggregating to Rs.2.50 per share for the financial year 2013-14, | 24-Jul-2014 | |
22-May-2014 | D | Suven Life Sciences Limited has informed the Exchange that the Board of Directors of the company at its meeting held on May 22,2014 has recommended dividend Re.0.50 paisa per share(50% of face value Rs.1.00 each) with an additional Special Silver Jubilee year dividend of Rs.2.00 per share (200% of face value of Rs.1.00
each), aggregating to Rs.2.50 per share for the financial year 2013-14, | 24-Jul-2014 | |
14-May-2013 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 14, 2013, inter alia, has recommended Dividend Re. 30 paisa per equity share of face value of Re. 1/- each (30%) for the financial year ended March 31, 2013 the dividend will be paid on and from August 27, 2013, subject to the approval of Members in the ensuing Annual General Meeting. | 01-Aug-2013 | |
14-Aug-2012 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 14, 2012, inter alia, has recommended Dividend Re. 0.30 paise per equity share of face value of Re. 1/- each (30%) for the
financial year ended March 31, 2012 the dividend will be paid on and from October 12, 2012, subject to the approval of Members in ensuing Annual General Meeting. | 17-Sep-2012 | |
30-May-2011 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2011, inter alia, has recommended dividend Re. 0.25 paisa per equity share of face value of Re. 1/- each (25%) for the financial year ended March 31, 2011 the dividend will be paid on and from August 28, 2011, subject to the approval of Members in ensuing Annual General Meeting. | 01-Aug-2011 | |
30-Apr-2010 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 30, 2010, inter alia, has recommended Dividend Re. 0.25 paise per equity share of face value of Re. 1/- each (25%) for the financial year ended March 31, 2010., subject to the approval of Members in ensuing Annual General Meeting. | 19-Jul-2010 | |
28-Jul-2009 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 28, 2009, inter alia, has approved the following:
1. The Board recommended Dividend Re 0.25 paise per equity share of face value of Re 1/- each (25%) for the financial year ended March 31, 2009, subject to the approval of Members in ensuing Annual General Meeting. | 14-Sep-2009 | |
25-Jul-2008 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 25, 2008, inter alia, has recommended Dividend @ 25% of face value of Re 1/- each (Re 0.25 paise per share) for the financial year ended March 31, 2008, subject to the approval of Members in ensuing Annual General Meeting. | 11-Sep-2008 | |
31-Jul-2007 | D | Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 31, 2007, inter alia, has transacted the following:
1. The Board has recommended Dividend @ 25% p.a. for the financial year ended March 31, 2007, subject to the approval of Members in ensuing Annual General Meeting. | 21-Sep-2007 | |
01-Aug-2006 | D | 50% Dividend | 25-Sep-2006 | |
26-Aug-2005 | D | 50% Interim Dividend | 05-Sep-2005 | |
15-Mar-2007 | B | SUB: Sub Division and Bonus issue of equity shares of Suven Life Sciences Limited (Scrip Code 530239)
Trading Members of the Exchange are hereby informed that, Suven Life Sciences Limited has fixed the Record Date for the purpose of sub division and bonus issue.
COMPANY NAME
Suven Life Sciences Limited
CODE
530239
RECORD DATE
02/04/2007
PURPOSE
Sub Division of existing equity shares from every ONE equity share of Rs.2/- each into TWO equity shares of Re.1/- each. AND Issue of ONE bonus equity share for every ONE equity share held.
SUB-DIVIDED PAID-UP VALUE
Re.1/-
SUB-DIVIDED PAID-UP VALUE & EX-BONUS W.E.F.
23/03/2007 DR-248/2006- 2007
The auction in the equity shares of Suven Life Sciences Limited in Dematerialised Securities - Rolling Settlement Segment on 23/03/2007, 26/03/2007 and 28/03/2007 will be conducted as per face value of Rs.2/- each and on cum-bonus basis. Trading members are, therefore, requested to take abundant precautions while mentioning the rates for offering the equity shares of the said company in auction on the said dates.
The scrip will be No Delivery from 23/03/2007 (DR-248/2006-2007) to 30/03/2007 (DR-002/2007-2008).
Note :-
i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Re.1/- paid up w.e.f. 23/03/2007.
ii. ISIN No. INE495B01020 of Rs.2/- paid up will not be valid for transactions done on the Exchange on or after 20/03/2007, except for the auction transactions, which will be conducted on 23/03/2007, 26/03/2007 and 28/03/2007 respectively.
iii. The new ISIN Number for Re.1/- paid up will be informed to the market by a separate notice. | 02-Apr-2007 | 1:1 |
12-Oct-2022 | R | 1:2 Right Issue of Equity Shares
Trading Members of the Exchange are hereby informed that, Suven Life Sciences Ltd. has fixed Record date for the purpose of Rights Issue of Equity Shares. The transactions in the Equity Shares of the Company should be done on Ex-Rights basis with effect from the under mentioned date :-
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME
& CODE
Suven Life Sciences Ltd.
(530239)
RECORD DATE
18/10/2022
PURPOSE
Issue of 1 (One) Equity Share of Re. 1/- each for cash at a premium of Rs.54/- per share on rights basis for every 2 (Two) Equity Shares held.
Ex-Right basis from Date & Sett. No.
17/10/2022
DR-137/2022-2023
Trading Members of the Exchange are requested to take note of it.
(As Per BSE Notice Dated on 13.10.2022) | 18-Oct-2022 | 1:2 |
06-May-2024 | BC | Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2024
Re-appointment of Managing Director | 01-Nov-2024 | |
21-Oct-2024 | BC | SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve consider and approve among other thing | 29-Oct-2024 | |
29-Jul-2024 | BC | SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2024 inter alia to consider and approve With reference to above subject pursua | 05-Aug-2024 | |
06-May-2024 | BC | Annual General Meeting & Closure of Register of Members & Share Transfer Books
Outcome of 35th Annual General Meeting held on 02nd August, 2024
(As Per BSE Announcement dated on 02.08.2024) | 02-Aug-2024 | |
06-May-2024 | BC | Annual General Meeting | 31-Jul-2024 | |